Advertise on podcast: Dirty Little Secrets: Telling the Truth on Healthcare

Every October we talk about breast cancer awareness, which mostly means remembering your mammogram and wearing pink. We miss the opportunity to talk about breast cancer risk, and how risk can be used to inform and improve how people are screened for breast cancer. The American Cancer Society surveyed 33,000 women and 99% of them knew family history raises breast cancer risk. But more than 85% of women who get diagnosed don’t have any family history, and most thought they were at low risk. No family history is also not the same as no genetic risk. In the WISDOM trial, a third of women who turned out to carry a high-risk inherited mutation had no family history, and no idea of their increased risk. Dr. Laura Esserman, a breast surgeon at UCSF and the lead investigator on the WISDOM trial, has spent her career arguing that breast cancer is not one disease and modern cancer treatment reflects that. But we still screen most women like they are all the same; our screening protocols haven’t really changed since the 1980s. “If it doesn’t make sense for treatment, how could it possibly make sense for screening?” WISDOM put that question to 28,372 women. Half kept annual mammograms, half were screened based on their actual risk, determined from a one-time genetic test covering BRCA1, BRCA2, PALB2 and the rest, plus a polygenic score and breast density. Highest risk patients were screened every six months; lowest risk meant waiting until 50 for a mammogram. The results were published in JAMA and showed that risk-based approach was successful. Risk-based screening was non-inferior on late-stage cancers, 30 per 100,000 person-years against 48, and among the highest-risk women, the ones screened every six months, there were no stage IIB or worse cancers at all. And it took thousands fewer mammograms to get there. When women were given the choice instead of being randomized, 89% picked the personalized arm. Esserman thinks the public is less afraid of changing this than the medical profession is. The genetic test costs about $250, once, which is cheaper than a mammogram. But mammography happens in a radiology department, and radiology is a revenue line. Currently mammograms are covered under the ACA, genetic testing coverage is more restricted. The data also informs on the ability to prevent breast cancer, when we identify patients at risk. ‘Baby tamoxifen’, a quarter of the standard dose, taken for three years, cuts a high-risk woman’s risk in half, and at that dose most of the side effects go away. But tamoxifen is now generic and no pharma sales team has a reason to teach doctors about it, so most women at elevated risk aren’t offered it. Knowing your risk informs how to screen for breast cancer and whether prevention strategies are right for you and your level of risk. But people need access to their risk information, and that information is powerful. Importantly, one thing Esserman wants every woman to hear, regardless of your age and whenever your last mammogram was. If you feel a new lump, get it checked. The fast ones show up between scans; don’t wait. Esserman LJ et al. “Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.” JAMA, 2026. https://jamanetwork.com/journals/jama/fullarticle/2842903 Join WISDOM Open to women 30 to 74 who have never had breast cancer, enrolling across the US. https://www.thewisdomstudy.org/get-involved/ — enrollment runs through athena-wisdom.org

If your company has more than about 500 employees, the card in your wallet probably says Aetna or United or another insurance company- but none of them are actually paying for your care. Your employer is, with your premium dollars. 67% of workers are in self-funded plans, which means the money from your paycheck and your employer’s revenue goes into a trust account. The insurance company is hired as a third-party administrator (TPA) to process claims against it. Lena’s math: rather than hand Aetna $100 in premium, the employer keeps $98 in a claims fund and pays Aetna $2 to administer it. That $98 is governed by ERISA, a 1974 law protecting employee benefit plans. Under ERISA the employer is a fiduciary: the money must be spent in the interest of the plan and its members. The key point most employers miss: you cannot delegate that fiduciary responsibility. Courts have held that anyone exercising control over plan assets is a fiduciary too, regardless of what the contract calls them. “You can call yourself whatever you want. If you exercise any level of control over that money, you yourself are a fiduciary.” Ebad Khan is a lawyer who did not come up in healthcare, which allows him to see things differently. He landed at a small out-of-network hospital in Houston as a young attorney with no stake in how things were already done. “There’s a huge presumption that you’re having to overcome,” he says, that institutions this old, doing things this way, must be doing them correctly. He didn’t buy it. Over ten years, the claim-by-claim disputes stopped looking individual. “Everything is just a little tilted. And you start asking yourself why.”. What's happening is that your money is being spent to increase the revenue of the TPA or insurance company in a way that does not improve your / plan members care. Repricing. A provider bills $100. The TPA routes it through a repricing firm, which decides it is worth $50, on their own. But the TPA tells the employer it negotiated that discount and takes a cut of the “savings,” often 20 to 30 percent. No negotiation happened, the provider got screwed, and the TPA took part of the bill for doing nothing. Financial conflcts: The big TPAs are publicly traded entities with fiduciary responsibility to their shareholders. To know what a health plan cares about, see what it tells Wall Street. This runs into a conflict because ERISA settles the hierarchy on paper, where members are first, but Khan is careful not to call the matter settled in practice. Some things are permissible, some are not, most sit on a scale, and somebody has to rule. For years nobody asked what was legal. His metaphor is speeding: five over, then ten, then fifteen, until somebody pulls you over. If you are an employee, that money is partly yours, and ERISA gives you standing over how that money is spent. Plaintiffs’ lawyers already know it. Khan describes them approaching employees directly: “We can represent you against your employer and against your TPA... to make sure the money you’re contributing into this health plan is being used for you.” Employees have already sued Johnson & Johnson, Wells Fargo, JPMorgan Chase, Macy’s and many others over how their benefit plans were managed. Courts are still working out how far the theory reaches — one set of claims against JPMorgan was allowed to proceed in March 2026, others are on appeal — but no employer wants to be the next name on a complaint. Could that exposure could be a lever for change? It is why Khan tells legal departments they would rather be plaintiff than defendant. The cheaper opening move belongs to employees: ask whether your plan is self-funded, and whether your TPA keeps a percentage of the “savings” it reports. It is benefits season. “The opportunity to be naive about these things is gone.” This episode is not legal advice.

Hannah Mamuszka and Lena Chaihorsky bring on Russell DuBose, VP of Human Resources at Phifer, a family-owned manufacturer in West Alabama, to tell an unforgettable story. In 2017 DuBose — a retired Army colonel with no healthcare background — took over benefits, and two months later stood in front of a CEO-chaired committee holding numbers he didn't yet know were bad: over $12,000 per employee per year, fewer than 40% of members with a primary care physician, and prescription adherence he calls "in the cellar." Asked what he intended to do about it, he applied the only method Phifer knew, the Lean Six Sigma strategy the company had used for twenty years. Dave Chase's CEO's Guide to Restoring the American Dream became the blueprint. His first conclusion was that his broker was his first problem — they worked for him, but he was not the customer — so he ran an RFP contingent on the winner signing a transparency agreement. What followed was a seven-year roadmap executed by a team of three: an on-site primary care clinic, direct contracts with prices that now haven't risen in a decade, a nurse navigator who built a quality-ranked specialty network, a transparent pass-through PBM, an on-site pharmacy funded entirely by dispensing fees with no copay, physical therapy with no cost share and no visit limits. The costs: flat in absolute dollars across 2020–2024, down 4% in 2025, with compound annual growth under 1.4% over ten years. The care: over 90% with a primary care physician, over 95% pharmacy adherence, member out-of-pocket share down from 19% to under 7%. DuBose's closing explanation is the thesis of the whole show — he didn't spend new money, he removed waste, and he estimates the middle was taking 40 to 50 cents of every dollar. Key takeaways The team is three people. DuBose, a healthcare manager, and an assistant, with a nurse navigator on the clinical side. The broker was the first thing to fix, not the carrier or the PBM. He describes the prior arrangement as the inverse of what an advisor relationship appears to be: they worked for the carriers and the stop-loss market, and he was the money rather than the client."Disruption" can be good. Phifer made hundreds of changes over ten years to improve member experience, but what they were disrupting was a business model that increased costs without improving care.Better care and flat cost are possible when you remove the middlemen. Phifer added thousands of encounters, a pharmacy, physical therapy, behavioral health and GLP-1 coverage while spending the same money, by taking services out of the retail market rather than by restricting access.The question for employees, not just employers: when did your company last examine its relationship with its broker and its PBM, and what does that relationship mean for the drugs you're offered?Relevant links Health Rosetta — healthrosetta.orgPhifer Incorporated — phifer.comDave Chase, The CEO's Guide to Restoring the American Dream https://healthrosetta.org/ceoguide/ Lean Six Sigma: https://en.wikipedia.org/wiki/Lean_Six_SigmaKaizen Event: https://kaizen.com/insights/kaizen-event/

Hannah Mamuszka and Lena Chaihorsky interview entrepreneur Mark Cuban about why U.S. drug and healthcare prices are so high — and what he's building to counter them. Cuban walks through the drug supply chain: brand manufacturers sell to three dominant distributors, then pharmacy benefit managers (PBMs) — the three largest of which are owned by or own major insurers — use rebates to set formulary placement, which he argues drives list prices up and can block patients from the drugs their doctors prescribe. He describes the gap between a drug's list price and its much lower "net" price after confidential rebates, and argues that opacity and confidentiality clauses keep even self-insured employers from knowing what they actually pay. His prescription: transparency and direct contracting ("if you can schedule it, you can negotiate it"), plus his ventures — Cost Plus Drugs (cost + 15% markup), Cost Plus Wellness, a Dallas plant making shortage drugs, and a proposed bank-account-based alternative to insurance (the "10 plan"). He also urges employers to run their contracts through AI tools to spot unfavorable terms. Key takeaways The drug-pricing problem is structural: three big distributors, three big PBMs vertically integrated with the three big insurers, and rebate-driven formulary placement that Cuban argues rewards high list prices over patient affordability.List price ≠ net price: confidential rebates create a large gross-to-net gap, and confidentiality clauses keep even self-insured employers (who bear the cost) from seeing real prices.Cuban's counter-model is transparency plus direct contracting — buying care and drugs at negotiated/Medicare-referenced rates rather than through opaque insurer/PBM arrangements.Practical tip he offers employers: feed carrier and PBM contracts into an AI tool to flag undefined terms and unfavorable clauses.Relevant links FTC interim staff report on PBMs (market concentration, vertical integration): https://www.ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdfKFF 2025 Employer Health Benefits Survey (self-funded plan share): https://www.kff.org/health-costs/2025-employer-health-benefits-survey/CVS Caremark's Zepbound → Wegovy formulary change (Mass.gov notice): https://www.mass.gov/news/cvs-caremark-decides-to-remove-zepbound-from-cvs-caremark-formularyMark Cuban’s Cost Plus Drugs (15% markup, Dallas manufacturing): https://www.markcubancostplusdrugcompany.com/FDA GDUFA generic drug (ANDA) fee rates: https://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendmentsKFF on ACA Marketplace deductibles: https://www.kff.org/affordable-care-act/what-we-know-so-far-about-2026-aca-marketplace-enrollment-premiums-and-deductibles/

Episode 6 — Greg Baker (AffirmedRx): The Rebate Shell Game and a Different Kind of PBM Hannah Mamuszka and Lena Chaihorsky interview Greg Baker, founder and CEO of AffirmedRx, a pharmacy benefit manager structured as a public benefit corporation which was recently named No.5 on the Inc. 5000. Baker, a pharmacist who spent years running on-site pharmacies for large employers, argues the drug-pricing system isn't broken but "working as designed" to maximize shareholder profit. He explains how the dominant PBMs make money as a percentage of drug cost, creating an incentive to favor expensive, highly rebated brands over cheaper generics, and how manufacturers must compete on rebate size for formulary placement, using Humira and Enbrel as his example. He describes what he calls a rebate "shell game," in which PBMs route rebates through offshore group purchasing organizations (Express Scripts' Ascent, in Switzerland) to obscure how much they keep. AffirmedRx, he says, charges a flat per-claim fee, passes rebates through fully, and caps executive pay. He points to recent ERISA lawsuits against employers (J&J, Wells Fargo, JPMorgan) as a turning point. A closing segment covers pharmacogenomics: why a person's metabolism affects whether a drug works, and how a cheek-swab test could reduce trial-and-error prescribing. Key takeaways AffirmedRx is a public benefit corporation charging a flat per-claim fee (not a percentage of drug cost), who says its incentives align with clients rather than favoring expensive, highly rebated drugs.The core mechanism Baker targets is rebates: manufacturers compete on rebate size for formulary placement, which he argues pushes list prices up and can force patients to switch drugs for financial rather than clinical reasons.Transparency is the throughline: Baker describes offshore rebate-aggregator GPOs (like Express Scripts' Ascent) as designed to obscure how much money PBMs keep, and urges employers to demand drug-level rebate data.Pharmacogenomics matter in many diseases, including mental-health, pain, and ADHD drugs, where using genetics to determine metabolism of drugs shorten trial-and-error.Relevant links AffirmedRx (public benefit corporation PBM): https://affirmedrx.com/FTC settlement with Express Scripts referencing its Switzerland GPO "Ascent": https://www.ftc.gov/news-events/news/press-releases/2026/02/ftc-secures-landmark-settlement-express-scripts-lower-drug-costs-american-patientsERISA drug-benefit fiduciary lawsuits (J&J, Wells Fargo, JPMorgan) overview — Jones Day: https://www.jonesday.com/en/insights/2026/05/rising-scrutiny-of-employer-health-plan-administration-erisa-fiduciary-litigation-federal-transparency-initiatives-stateGallagher / Osceola County settlement over undisclosed commissions: https://floridapolitics.com/archives/589098-osceola-schools-settle-lawsuit-over-insurance-consultants-secret-commissions/

Hannah Mamuszka and Lena Chaihorsky take on the drug pricing debate from the patient's side, where the question is not what a drug costs but whether it works for the person taking it. Chaihorsky frames it with a metaphor that runs through the episode: we argue endlessly over the price of milk while ignoring that the whole family is lactose intolerant. Mamuszka tells a story that shaped her career. As a young scientist at a small pharma company, she spent years developing a biomarker for a drug at the FDA's suggestion, only for the agency to drop the requirement and for her CEO, at the launch party, to explain that they would treat every patient the label allowed because there were investors to repay. The drug worked in roughly 38% of patients and caused serious side effects in about 40%, and the biomarker could tell those groups apart. They trace how that logic became structural, including the FDA's early-2000s move toward companion diagnostics for all targeted therapies, which collapsed under industry pushback. Chaihorsky then walks through the economics that decide which drugs patients can get when no biomarker stands in the way: PBM formularies rank-ordered by rebate rather than by mechanism of action, step therapy, and a pharmacy-versus-medical budget split that leaves no one owning the cost of being wrong. Their closing asks are simple. Patients should ask how their doctor knows a drug will work for them. Employers heading into benefits season should ask who their PBM is and what its contract rewards. Key takeaways The price of the drug is only half the conversation, whether it works is the other.Response rates are far lower than most people assume. Schork's 2015 Nature analysis found the ten highest-grossing US drugs help between 1 in 25 and 1 in 4 of the people who take them.Nothing rewards a higher response rate. A drug's price is the same whether it works in 15% of patients or 80%.PBMs are paid on rebates rather than net cost, so formularies are rank-ordered by what pays best rather than by who is likely to respond. Using biomarkers to predict response would break that model, which is a reason to expect resistance rather than a reason it doesn't work.Pharmacy and medical spend sit in separate budgets, so a wasted prescription and the hospitalization it causes are never added together, and nobody is accountable for the total.The question for patients: how do you know this drug will work for me? The question for employers: who is our PBM, and is our formulary built on rebates or on evidence?Relevant links Schork NJ, "Personalized medicine: Time for one-person trials," Nature 2015;520(7549):609–611 — the source of the "1 in 25 to 1 in 4" figure and the imprecision-medicine graphic Lena describes: https://www.nature.com/articles/520609aFTC interim staff report on pharmacy benefit managers (July 2024) — the top three PBMs processed nearly 80% of the ~6.6 billion US prescriptions dispensed in 2023: https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemenSubstack, "The Price of Drugs Is Only Half the Problem": https://hannahmamuszka.substack.com/p/the-price-of-drugs-is-only-half-the?r=4n5pb&utm_campaign=post-expanded-share&utm_medium=web

Hannah Mamuszka and Lena Chaihorsky interview Kristine Ashcraft, a molecular biologist who has worked in pharmacogenomics (PGx) since 2000, first at Genelex, one of the earliest labs to offer the testing, and later as founder of the clinical-decision-support tool YouScript. Ashcraft traces the field's slow adoption despite strong evidence, explaining how most people carry gene variants affecting how they metabolize common drugs, using a "liver highway" analogy: some people have fewer or more "lanes" (enzyme activity), and drugs, foods, and other medications can shut lanes down. YouScript's clinical studies showed large reductions in hospitalizations, ER visits, and deaths, and the European PREPARE trial's 30% drop in adverse drug reactions. A recurring theme is misaligned incentives — she describes a hospital CFO explaining they make money from the very hospitalizations that PGx would prevent. The conversation covers the Right Drug Dose Now Act, DPYD testing in oncology (where the wrong genotype plus a common chemo drug can be fatal), and practical advice: get tested once, log dangerous drugs as "allergies" so they follow you, and advocate for yourself. Key takeaways Pharmacogenomic variation is nearly universal; most people carry at least one clinically actionable variant affecting how they process common drugs, and yet testing still isn't routine, largely because of misaligned financial incentives and gaps in clinician education.The evidence base is strong: PGx-guided prescribing has produced large reductions in hospitalizations, ER visits, and adverse drug reactions in both U.S. studies and the multi-country European PREPARE trial.Some drug-gene interactions are life-or-death: DPYD testing before 5-FU/capecitabine chemotherapy, now backed by FDA boxed warnings and NCCN guidelines, can prevent fatal toxicity.Practical self-advocacy: pharmacogenomic testing is a one-time, low-cost test; logging a dangerous drug-gene result as an "allergy" helps it travel across fragmented medical records.Relevant links PREPARE study — 12-gene panel, 30% reduction in adverse drug reactions (The Lancet, 2023): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01841-4/abstractYouScript home-health RCT (52% fewer readmissions, 85% mortality reduction), PLOS ONE: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289536/CPIC guideline for CYP2D6/CYP2C19 and SSRIs (citalopram/escitalopram dosing): https://pmc.ncbi.nlm.nih.gov/articles/PMC4512908/FDA codeine boxed warning (ultrarapid CYP2D6 metabolism): https://www.ncbi.nlm.nih.gov/books/NBK100662/NCCN/FDA DPYD testing before fluoropyrimidine chemotherapy: https://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidineRight Drug Dose Now Act (H.R. 2471, 119th Congress): https://www.congress.gov/bill/119th-congress/house-bill/2471/text

Hannah Mamuszka and Lena Chaihorsky talk with Jane Cheshire Gilbert, a CPA who spent two decades running the health plan for the Teachers' Retirement System of Kentucky (TRS) and became an unlikely pioneer in pharmacogenomics. Serving tens of thousands of retired teachers — many in their 80s and 90s, on an average of 15 medications — Gilbert treated genetic testing not as a clinical curiosity but as a fiduciary tool: if a plan is paying full price for a blood thinner or antidepressant a member's body can't use, everyone loses. She recounts building a program with Coriell Life Sciences and the Know Your Rx Coalition, testing roughly a third of the Medicare-eligible population, and a published study showing meaningful per-member savings and fewer hospitalizations. The conversation is candid about the rebate machine (which she used dollar-for-dollar to hold premiums down), why insurers wouldn't pay for testing that saved them money, and her prescription for the next generation of purchasers: end direct-to-consumer drug advertising, require comparative-effectiveness research, and make real prices visible through reference-based pricing. Her closing line summarizes the whole show: "Mad is not a strategy." Key takeaways A fixed-budget purchaser has nowhere to hide costs, which is exactly why pharmacogenomics made sense here: paying full price for a drug a member's genetics won't let them use is pure waste, clinically and financially.The program has real evidence behind it — a published study of the TRS/Coriell program documented significant per-member savings and reduced hospitalizations across thousands of Medicare-eligible retirees.The incentives are backwards: the insurer that captured most of the savings wouldn't pay for the testing that produced them, because under a fully insured arrangement those savings were its margin.Gilbert's three systemic fixes — ending direct-to-consumer drug ads, requiring drug-vs-drug (not drug-vs-placebo) comparative-effectiveness research, and reference-based pricing tied to Medicare — are areas where purchasers across the political spectrum tend to agree.Relevant links Published study of the TRS Kentucky PGx + medication-management program (Journal of Personalized Medicine, 2022): https://www.mdpi.com/2075-4426/12/3/421Coriell Life Sciences' TRS Kentucky case study: https://www.coriell.com/resources/trs/Clopidogrel (Plavix) and CYP2C19 genotype — NIH Medical Genetics Summaries: https://www.ncbi.nlm.nih.gov/books/NBK84114/CPIC clopidogrel/CYP2C19 guideline (2022 update): https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2526Direct-to-consumer drug advertising — U.S. and New Zealand only (USC Schaeffer): https://schaeffer.usc.edu/research/should-the-government-restrict-direct-to-consumer-prescription-drug-advertising-six-takeaways-from-research-on-the-effects-of-prescription-drug-advertising/

Hannah Mamuszka and Lena Chaihorsky make the case that diagnostics — not just drugs — are the key to controlling healthcare spending, and that the U.S. systematically underuses them. They lay the groundwork for the series: primary diagnosis (what's actually causing your symptoms), the "diagnosis of exclusion" trap, and two kinds of tests that determine whether a prescribed drug will work for you — pharmacogenomic tests (how your genes affect drug metabolism) and response-predicting diagnostics (whether you'll respond at all). The recurring villain is economics: insurers balk at a $200 test to protect a $10 prescription, ignoring the clinical and downstream costs; physicians skip testing to spare patients surprise bills; and because most drugs work in only a minority of patients, the resulting churn is profitable. They argue this is why response-predicting tests in areas like rheumatoid arthritis exist but aren't covered — using them would upend rebate-driven formularies. The through-line: we'll pay almost anything for a drug, but won't pay to find out if it will work. Their closing prompt for listeners: ask your doctor how they know this drug is right for you. Key takeaways Diagnostics are the "GPS" of care: without an accurate diagnosis and the right tests, treatment becomes expensive trial-and-error — yet the U.S. spends a small fraction on diagnostics relative to drugs.Two kinds of tests can tell you whether a drug will work before you take it: pharmacogenomic tests (how your body metabolizes a drug) and response-predicting tests (whether you'll respond at all).The economics are backwards: a cheap test that prevents a wrong prescription is often refused because the savings and harms are downstream, while the churn of failed prescriptions is profitable.The patient's question — for any new prescription — should be: "How do you know this drug is right for me, and is there a test that would tell us?"Relevant links Check to see if your drug has a pharmacogenomic test associated with prescription: https://www.clinpgx.org/Diagnostic errors in the U.S. — overall error rate and harms (NIH/National Academies review): https://www.ncbi.nlm.nih.gov/books/NBK588113/How effective are common medications — realistic drug-efficacy meta-analyses (BMC Medicine): https://link.springer.com/article/10.1186/s12916-015-0494-1Genetic determinants of warfarin dose (VKORC1, CYP2C9) — PLOS Genetics: https://journals.plos.org/plosgenetics/article?id=10.1371%2Fjournal.pgen.1000433Inadequate response to first-line anti-TNF therapy in RA (~30–40%): https://journals.sagepub.com/doi/10.1177/1759720X221114101FDA approval standards and the absence of comparative-effectiveness requirements (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMp0906490

In the debut episode of Dirty Little Secrets, Hannah Mamuszka and Lena Chaihorsky introduce themselves and the podcast's central thesis: that the U.S. healthcare system is built on financial incentives that reward treatment over prevention and volume over value, systematically blocking patients from the best data-driven care. Mamuszka, a molecular biologist who moved from cancer drug development into diagnostics, and Chaihorsky, who came to the field through math and finance, each recount early-career moments when validated science was undervalued by the payment system — a high-risk-pregnancy test reimbursed at $11, and a urine test that could spare men unnecessary prostate biopsies but was resisted by urologists whose income depended on the procedure. They argue that patients meet the system at their most vulnerable, unable to shop as empowered consumers, and that misaligned incentives — including the ACA's medical loss ratio, which they contend removes insurers' incentive to cut costs — keep prices climbing. Citing research that rising premiums have eroded decades of middle-class wage gains, they make the case for a more consumer-driven, data-personalized system and invite listeners to start asking harder questions. Key takeaways The podcast's throughline: U.S. healthcare pays generously for treatment (surgery, drugs, hospitalizations) but poorly for the information — diagnostics, screening, risk data — that would let patients be treated as individuals rather than averages.Fee-for-service can create perverse incentives: the hosts describe a validated test that could reduce unnecessary prostate biopsies going unused because biopsies are a revenue source — a systems problem, not a critique of individual doctors.The ACA's medical loss ratio (insurers must spend 80–85% of premiums on care) is framed as a misincentive: since profit is a slice of a bigger pie, there's little reward for lowering total costs.Rising premiums have quietly consumed middle-class wage growth, which the hosts argue should reframe healthcare from an abstract cost into a personal, paycheck-level issue.Relevant links ACA Medical Loss Ratio and rebates — CMS: https://www.cms.gov/marketplace/private-health-insurance/medical-loss-ratio"A Decade of Health Care Cost Growth Has Wiped Out Real Income Gains for an Average US Family" (Auerbach & Kellermann, Health Affairs 2011): https://www.healthaffairs.org/doi/10.1377/hlthaff.2011.0585Employer premium growth and wage stagnation/earnings inequality (JAMA, 2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC10792464/Exo mdx urine test to help men avoid prostate biopsy (Harvard Health): https://mdxhealth.com/exo-mdx-for-physicians/"Unintended Consequences of the ACA's Medical Loss Ratio Requirement" (Health Affairs Forefront): https://www.healthaffairs.org/content/forefront/unintended-consequences-aca-s-medical-loss-ratio-requirement